Medtronic Spins Off Diabetes Business: Strategic Refocus and MiniMed IPO Drive Next-Gen Growth

▲ Source of the article: Eshare Medical Device Collection

▲Please indicate the above source at the beginning of the article when reprinting.

In 2025, Medtronic entered its critical transformation period.

As a global leading medical technology company, Medtronic not only continues to expand in its core business areas but also announced a significant strategic adjustment to its diabetes business – spinning it off from the company as a whole to become an independent publicly traded company.

This decision marks a strategic evolution for Medtronic in optimizing its business portfolio and focusing on high-growth, high-margin areas.

Medtronic Shines in Financial Performance for FY2025, with Significant Progress in Sustained Growth and Innovation in Key Areas.

In FY2025, Medtronic's total revenue was $33.627 billion, with an organic growth of 4.9%.

ThisOneThe growth was mainly driven by the strong performance of its Cardiovascular, Neuroscience, Diabetes, and Medical Surgical departments.

Performance of Major Business Units

1. Cardiovascular：

Medtronic's cardiovascular business continues to expand in the 2025 fiscal year, particularly in the fields of Cardiac Rhythm Management and Percutaneous Coronary Intervention technologies.

The department achieved revenue of $12.48 billion.Organic growth of 6.3%, with particularly strong performance in interventional cardiac surgery (CAS) and structural heart disease (TAVR).

These technological advancements have strengthened Medtronic's leadership position in the global cardiovascular market.

2. Diabetes：

Diabetes business remains an important part of Medtronic, although it will be spun off in the near future.

Revenue of the Diabetes Division in FY2025For$2.755 billion,Organic Growth 11.5%, particularly in the strong performance of sales in automated insulin delivery systems and continuous glucose monitoring (CGM) products.

Medtronic's MiniMed 780G system continues to lead the market and has received highly satisfactory feedback in multiple international markets.

3. Neuroscience:

Neuroscience business also performed well in the fiscal year 2025, departmentRevenue$9.846 billion,Organic Growth5.2%。

Innovations in neuromodulation and spinal surgery, in particular, are helping Medtronic continue to capture market share.

Medtronic's spinal stimulators and deep brain stimulation systems (DBS) continue to gain clinical recognition and market adoption.

4. Surgical Operations (Medical Surgical):

The surgical department also showed low single-digit growth.Revenue for the 2025 fiscal year is$8.407 billion,Organic Growth 0.8%

The growth of this department is mainly attributed to Medtronic's innovative applications in advanced energy technology (Advanced Energy) and robotic surgical systems, such as the Hugo robot.

Medtronic announced in May 2025 that it plans to spin off its diabetes business from the company as a whole within the next 18 months, becoming an independent publicly traded company.

This strategic adjustment is an important initiative for Medtronic to optimize its business portfolio and enhance shareholder value.

Motivations for the Split

Focus on High-Growth Areas：Diabetes business is a high-growth area for Medtronic, but its business model differs significantly from other divisions of Medtronic. The diabetes business primarily targets end consumers (i.e., diabetes patients), whereas other Medtronic businesses focus on healthcare institutions and doctors as their main customers.

Spinning off the diabetes business will allow Medtronic to better focus on its core medical technology fields aimed at high profitability and high growth.

Improve Operational Efficiency：The independent diabetes company will be able to concentrate its resources on areas such as its innovative pipeline and automated insulin delivery systems without being constrained by other business operations, thereby enhancing operational efficiency and market responsiveness.

Maximization of Shareholder Value：Through the spin-off, Medtronic plans to unlock the value of its diabetes business, enabling it to operate independently and achieve a higher valuation in the capital markets.

At the same time, the spun-off diabetes company can have a more flexible capital structure and a more focused investment strategy.

Specific plans for the split

Medtronic Plans to Fully Spin Off Diabetes Business Through IPO and Subsequent Split

The split is expected to be tax-friendly, generate immediate earnings per share (EPS) growth for Medtronic shareholders, and is anticipated to enhance Medtronic's operational and gross margins.

The independence of the diabetes business will also enhance its global competitiveness, particularly in innovative fields such as automated insulin delivery and smart insulin injection systems.

The diabetes business has tremendous growth potential in the coming years.

Medtronic's MiniMed 780G system has already taken a leading position in the market and is expected to continue driving the company's expansion in the global market in the coming years.

As the demand for efficient and convenient treatment solutions continues to grow among people with diabetes, Medtronic's technological innovation and market penetration in the diabetes business will further accelerate.

1. The Growth of Automated Insulin Delivery Systems：With the promotion of products such as MiniMed 780G, the market demand for automated insulin delivery systems will continue to expand.

Such systems can provide more precise diabetes management and reduce the burden on patients' lives.

2. Innovation in Intelligent Injection Systems：Medtronic's innovations in smart injection systems (such as the InPen and Simplera systems) enable diabetes patients to manage their condition more efficiently.

The popularity of such products is expected to further drive the growth of the diabetes business.

3. Expansion of the Global Market：Medtronic's diabetes business not only holds a significant position in the U.S. market but also has broad market potential in Europe, Asia, and other regions.

With the increase in the number of diabetic patients worldwide, the diabetes business will welcome more growth opportunities.

In the fiscal year 2025, with Medtronic's continuous innovation and strategic adjustments, especially in the decision to spin off its diabetes business, the company is entering a brand-new stage of development.

The independence of the diabetes business will bring more flexibility and growth momentum to the company, while Medtronic itself will be able to focus more on its core high-profit growth areas.

It is expected that in the next few years, both Medtronic and its newly independent diabetes company will play increasingly important roles in the global medical technology market.

Scan the QR code in the image below to purchase.

‍